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Abstract
Background: Augmentation therapy involves the addition of a second drug, such as mood stabilizers, antipsychotics, and nutri-
tional supplements, to a primary antidepressant treatment. Studies on adding folic acid to a preexisting antidepressive regimen as
a form of augmentation therapy have had different and even controversial results.
Objectives: This study aimed to determine the effects that adding folic acid to a pharmaceutical diet with citalopram has on the
treatment of depression.
Methods: This double-blind randomized clinical trial was conducted in Kashan, Iran on 90 patients who suffered from depression.
Patients were allocated to study groups using random permuted blocks. One group (n = 45) received a dosage of 20 mg citalopram
in combination with 2.5 mg folic acid on a daily basis, and the other group (n = 45) received the same daily dose of citalopram with a
placebo for eight weeks. To measure the severity of each patient’s depression, the Beck depression inventory II (BDI-II) questionnaire
was used prior to starting the antidepressant therapy and was repeated four, six, and eight weeks after beginning the treatment. A
reduction from the original BDI-II scores that was greater than 50% was considered to be a response to treatment.
Results: The average depression scores before treatment were 30.11± 10.41 in the intervention group and 31.24± 10.26 in the control
group (P = 0.6). At the end of the study, the depression scores in the intervention and the control groups were 13.31± 6.57 and 19.11
± 8.59, respectively (P < 0.001). A reduction in the average depression scores of the intervention group was statistically significant
after six and eight weeks (P = 0.01 and P = 0.001, respectively). At the end of the study, the frequency of response to treatment was
73.3% in the intervention group and 40.0% in the control group (P < 0.001).
Conclusions: Folic acid, when used as a complementary therapy, can improve a patient’s response to antidepressants used for the
treatment of major depression.
Keywords: Major Depressive Disorder, Citalopram, Folic Acid, Augmentation Therapy
1. Background
Major depressive disorder (MDD) is a chronic mental
disorder with an estimated lifetime prevalence of 13% - 17%
in the United States (1, 2). Depression is the leading cause of
disability in developed countries and has been predicted
to become the most significant cause of disability world-
wide by 2020 (3). MDD causes a huge economic burden
for health systems, with the imposed burden in European
countries reaching €118 billion, most of which is related to
indirect costs, such as absence from work (4, 5).
Although new therapeutic options have emerged in re-
cent years, there are still many patients who do not re-
spond to first-line antidepressants (6, 7). Several strate-
gies have been proposed for patients with refractory de-
pression, including increasing the dosage of the antide-
pressant, switching the patient to new-generation medi-
cations, and adding another antidepressant medication to
the patient’s current treatment. However, these methods
are not always successful because of unpleasant side ef-
fects. Therefore, developing safer and more effective meth-
ods for the treatment of refractory depression would be ad-
vantageous (8).
Previous studies have investigated the role of nutri-
tional factors in treating neuropsychiatric disorders (9-11).
These studies have shown that a considerable portion of
patients with psychiatric disorders, including MDD, have
been reported as having low levels of different vitamins,
especially folate (12, 13). Augmentation therapy using fo-
late, vitamin B12, omega-3 fatty acids, and zinc supplemen-
tation are new methods that have been suggested to im-
prove depression and a patient’s response to a therapeutic
regimen with fewer side effects (14-16).
Few studies have examined the effects of folic acid sup-
plementation as an augmentation of the treatment of ma-
jor depression, and the results achieved by the few stud-
ies that exist are not univocal. Additionally, the concurrent
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use of citalopram with folic acid in treating MDD has not
yet been evaluated.
2. Objectives
Considering the existing controversies, in this study,
we evaluated the effects of the concurrent administration
of citalopram and folate in the treatment of MDD.
3. Methods
3.1. Study Participants
This double-blind randomized clinical trial was con-
ducted on 90 patients who were referred to the psychiatric
clinic of Kashan University of Medical Sciences in Iran. The
study site was a psychiatric clinic affiliated with the gov-
ernment that is the main referral center in the area. This
clinic provides outpatient psychiatric and psychological
services to children and adults.
The calculation to determine the required sample size
for this study was based on the results of a study performed
by Venkatasubramanian et al. who evaluated the effects of
the coadministration of fluoxetine and a different dosage
of folic acid (17). In their study, the frequency of response
to treatment was reported to be 52.6% in patients who re-
ceived high doses of folic acid and 21.7% in those receiving
low-dose folic acid. With a power of 80% and Z1-α/2 = 1.96
and with the use of the following equation, we concluded
that the required sample size of each group in our study
was 39. To allow for a 10% loss of participants, the sample
size was adjusted to 45 in each study group (Equation 1).
(1)n =
(
z1 − α2 + z1−β
)2
pq
(p1 − p2)2
Participants were recruited via convenience sampling
from those referred to our outpatient psychiatric clinic
who were depressed according to the Diagnostic and Sta-
tistical Manual of Mental Disorders IV Text Revision. For
this purpose, all patients who met the inclusion and ex-
clusion criteria were enrolled until completion of the re-
quired sample size (n = 90). All patients were residents of
Kashan city.
The inclusion criteria were an age of 20 - 50 years and
a Beck depression inventory score greater than 12. The
exclusion criteria were the use of antidepressants within
the last four weeks, signs of psychosis, mental retarda-
tion, a history of manic episodes, a history of taking psy-
chotropic drugs, and certain medical problems (anemia,
pregnancy, chronic diseases, etc.). Patients experiencing
severe drug reactions at any stage were excluded from the
survey. The total number of recruited cases was 100. How-
ever, five cases were omitted because of antidepressant us-
age within the last four weeks, three cases had psychosis,
and two cases were put aside because of a history of manic
episodes. Thus, the final sample size of the study was 90
cases (Figure 1).
The demographic and clinical data of the patients,
such as age, sex, education level, marital status, history of
depression, treatment with SSRIs, and history of anxiety
disorders, were recorded in a predesigned checklist.
The patients were divided into two equal groups, an in-
tervention group and a control group, using the permuted
block randomization method. For this purpose, 15 blocks
with a block size of six were used, and the blocks were clas-
sified by order of numbers. Both patients and researchers
were blind to the treatment allocation. The only person
who knew the allocation was the nurse who was in charge
of delivering the medications.
All ethical principles were respected in accordance
with Resolution 196/96 on research involving human sub-
jects. The ethics committee of Kashan University of Med-
ical Sciences approved the study and supervised all its
stages (approval code: p/29/5/1/458). This study was also
recorded in the Iran Center of Clinical Trials Registration
database (IRCT2014082518922N1). After being informed of
the study objectives, all participants signed a written con-
sent form.
3.2. Clinical Assessments
All study participants were visited by a psychiatrist at
the beginning of the study and at two-week intervals. In ev-
ery visit, patients were checked for exclusion criteria, treat-
ment adherence, and possible side effects.
To measure the severity of each patient’s depression
and anxiety, all participants were asked to complete the
second version of the Beck Depression Inventory question-
naire (BDI-II) and the Hamilton anxiety rating scale ques-
tionnaire (HAM-A) prior to group allocation. The BDI-II was
completed again four, six and eight weeks after the onset
of the study. The HAM-A was also completed by all patients
at the end of the treatment (the eighth week). Lower BDI-
II scores were considered to be the result of the study. Pa-
tients were divided according to their BDI-II scores into
mild (14 - 19), moderate (20 - 28), and severe (29 - 63) de-
pression categories. A decrease more of than 50% in a pa-
tient’s primary BDI-II score was reported as a response to
treatment.
A developed checklist was used for collecting data. The
checklist consisted of two parts. The first part gathered
the subjects’ demographic data, such as age, sex, height,
weight, marital status, education level, and history of MDD
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Figure 1. Study Flow Chart
and anxiety disorders. The second part contained clini-
cal information, including BDI-II scores (which were ob-
tained prior to the onset of the study and four, six, and
eight weeks into the treatment) and HAM-A (which were
obtained before and after the treatment). The content va-
lidity of the checklist was approved by four psychiatry and
psychology experts. The checklist’s reliability was deter-
mined using the interobserver method: In an initial pilot
study, the questionnaire was completed for five patients in
each group by three researchers not involved in creating
the checklist. Then, the degree and significance of agree-
ment between observers was calculated (r = 0.87).
3.3. Medications
All patients received 20 mg citalopram tablets (Sobhan
Pharmaceutical Company, Iran) per day for eight weeks.
The patients in the intervention group also received 2.5 mg
folic acid (Sobhan Pharmaceutical Company, Iran) per day,
and patients in the control group were given an identical-
looking placebo in addition to the citalopram. The drugs
were given once every two weeks at the time of the psychia-
trist’s visit. Patient adherence to treatment and side effects
were looked for at each appointment.
3.4. Statistical Analysis
The data were analyzed using SPSS software version 16
for Windows. The descriptive part of the analysis was re-
ported as absolute and relative frequency. The results of
the quantitative data analysis were expressed as mean ±
standard deviation. The Kolmogorov-Smirnov test was ap-
plied to assess the data distribution. A chi-squared test, an
independent t-test, a paired t-test, and a repeated measures
ANOVA were used for data analysis. Before analyzing the
data using the repeated measures ANOVA, assumptions,
including the type of data, randomness, normality, and
sphericity, were checked. Since Mauchly’s Test of Sphericity
indicated that the assumption of sphericity had been vio-
lated (P < 0.001), the Huynh-Feldt correction was applied.
All tests were two-tailed. The level of significance for all
tests was considered to be P < 0.05.
4. Results
In this study, 90 patients in two groups were surveyed,
and all patients completed the treatment course. Of the 90
patients, 56 (62.2%) patients were female. The average age
of the patients was 35.73 ± 9.57 years; the minimum age
was 20 years old and the maximum was 50 years old.
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The demographic and clinical characteristics of the pa-
tients are shown according to treatment group in Table 1.
The baseline clinical characteristics of the patients are also
shown in Table 1. The average depression scores of the pa-
tients before treatment was 30.11 ± 10.41 in the interven-
tion group and 31.24± 10.26 in the placebo group (P = 0.6).
The mean HAM-A anxiety score before treatment was 34.24
± 9.09 in the intervention group and 35.82 ± 9.57 in the
placebo group. This difference between the scores of the
two groups before intervention was not statistically signif-
icant (P = 0.42). The treatment outcomes are shown in Ta-
ble 2. The repeated measures ANOVA showed that the re-
duction in depression scores were different between the
groups (P < 0.001) (Figure 2).
Group
Case
Control
Before
Intervention
4th
Week
6th
Week
8th
Week
M
ea
n
 D
ep
re
ss
io
n
 S
co
re
35.00
30.00
25.00
20.00
15.00
10.00
Figure 2. Repeated Measures Analysis of Depression Scores
5. Discussion
The present study was designed to investigate the ef-
fects of the coadministration of folic acid and citalopram
in patients with MDD. Prescribing 2.5 mg of folic acid as a
supplement increased the antidepressant action of citalo-
pram.
Previous studies have investigated the potential effect
of folate augmentation of antidepressants. Passeri et al.
compared folate with trazodone added to standard med-
ication for the treatment of depression in patients with
dementia (18). Another survey confirmed that folic acid
greatly improved the effect of fluoxetine in the treatment
of major depression (19). Similar results that are consistent
with our findings have been reported in other studies as
well (20-22). Papakostas et al. confirmed that L-methyl fo-
Table 1. Patient Demographics and Clinical Characteristicsa
Variable Group P Value
Acid Folic Placebo
Age 35.11± 8.62 36.35± 10.49 0.54
Sex 0.38
Male 19 (42.2) 15 (33.3)
Female 26 (57.8) 30 (66.7)
Marital status 0.9
Single 12 (26.7) 10 (22.2)
Married 27 (60) 29 (64.4)
Divorced 3 (6.7) 2 (4.4)
Widow 3 (6.7) 4 (8.9)
Education 0.69
Primary school 12 (26.7) 11 (24.4)
Middle School 15 (33.3) 13 (28.9)
High school diploma 12 (26.7) 17 (37.8)
Academic degree 6 (13.3) 4 (8.9)
MDDhistory 0.16
No 29 (64.4) 35 (77.8)
Yes 16 (35.6) 10 (22.2)
Anxiety disorders 0.38
No 27 (60) 31 (68.9)
Yes 18 (40) 14 (31.1)
Depression severity 0.96
Mild 9 (20.0) 8 (17.8)
Moderate 10 (22.2) 10 (22.2)
Severe 26 (57.8) 27 (60.0)
BDI-II score 30.11± 10.41 31.24± 10.26 0.6
Hamilton score 34.24± 9.01 35.82± 9.57 0.42
aValues are expressed as mean± standard deviation or No. (%).
late is an effective adjunctive therapy in the treatment of
patients with MDD that is resistant to SSRIs (23).
Other studies have reported opposite findings. Chris-
tensen et al. disagree with the idea of the potentiation of
antidepressants with folate + B12 supplementation (24).
One review study addressed the effects of supplements
on the improvement of the therapeutic effects of antide-
pressant drugs. This study did not find sufficient evidence
to support the positive effects of folic acid (25). These con-
tradictions may be caused by the differences in prescribed
folic acid doses, the treatment duration, and the methods
used to measure the patients’ clinical response.
Our study indicated that the response to treatment was
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Table 2. Treatment Outcomesa
Variables Groups P Value
Folic Acid Placebo
BDI-II score
4th week 24.44± 9.19 27.38± 9.57 0.14
6th week 18.24± 7.97 23.0± 9.08 0.01
8th week 13.31± 6.57 19.11± 8.59 0.001
Response frequency
4th week 0 0 -
6th week 10 (22.2) 5 (11.1) 0.16
8th week 33 (73.3) 18 (40.0) 0.001
Depression scores reduction
4th week 5.67± 3.62 3.87± 4.07 0.03
6th week 11.87± 4.88 8.24± 5.87 0.002
8th week 16.8± 5.77 12.13± 6.55 0.001
Final depression severity 0.04
Mild 13 (61.9) 10 (30.3)
Moderate 7 (33.3) 15 (45.5)
Severe 1 (4.8) 8 (24.2)
Final Hamilton score 21.93± 9.41 27.18± 11.16 0.02
aValues are expressed as mean± standard deviation or No. (%).
significantly higher in both men and women in the folic
acid and citalopram group compared with the placebo
group. To our knowledge, only one study has mentioned
the effect of gender on the response to the augmentation
of treatment with folic acid. Coppen et al. reported that
men need relatively higher doses of folic acid to achieve
the positive effects (19). The role of gender was noticed by
other studies that surveyed the relationship between folic
acid and depression. Sanchez-Villegas et al. pointed out
that an inverse association exists between the amount of
folic acid intake and the prevalence of depression among
men, especially smokers, but no similar relationship was
found among women (26). In another study, Astorg et al.
observed a strong correlation between high levels of folic
acid and reduced incidence of depressive episodes among
men, but this association was not seen in women (27). Sim-
ilar results have been reported by Murakami et al. (28). On
the other hand, two other studies stated that the relation-
ship between folic acid intake and occurrence of depres-
sive symptoms was observed only in women (29, 30).
Another study evaluating the effects of two differ-
ent doses of folic acid on the efficiency of fluoxetine for
the treatment of depression showed that both men and
women would benefit from treatment augmentation with
folate but that higher doses were reported to be more ef-
fective in women than in men (17).
Currently, there is no valid reason for explaining these
differences, but psychosocial factors, genetics, individual
differences in drug metabolism and pharmacokinetics,
and food and drug habits may play a role.
We found that there were statistically significant dif-
ferences between the two groups in the responses of pa-
tients of both genders who were less than 35 years old to
the treatment, but of the patients who were older than 35
years old, a similar response was observed only in male pa-
tients. This aspect of study has not previously received at-
tention (31). Since folic acid deficiency is more common
in the older population, elderly people would rationally
benefit more from receiving folic acid than younger peo-
ple. Alternatively, age-related reductions in intestinal folic
acid absorption might be the reason for these results (32).
However, since our study subjects were not selected from
an older population, this possibility seems less likely.
According to current studies, the effects of the coad-
ministration of folate on improving the treatment of de-
pression are noticeable and well proved. Folic acid is es-
sential for various functions of the human body, includ-
ing processes related to the nervous system. Studies con-
ducted over the last few decades have shown that patients
with folic acid deficiency revealed psychological symp-
toms, such as depression and cognitive impairment (33,
34).
Folate level is thought to be associated with vari-
ous mood disorders. Previous studies have shown lower
plasma and red blood cell folate in patients with depres-
sion. Lower levels of folic acid have also been related to
longer and more severe depressive phases in bipolar pa-
tients (15, 35). In a group of studies that evaluated folic
acid levels in depressed patients, individuals with depres-
sion had the lowest serum levels of all patients studied,
and only individuals with alcohol dependence had similar
folic acid levels (36). Folic acid levels are thought to fluctu-
ate depending on the type of mood disorder. For example,
the percentage of individuals with low folic acid levels was
higher among patients with melancholic depression com-
pared to those with nonmelancholic depression (37).
There have been very few studies conducted on the lev-
els of folate and depression in the general population. Tol-
munen et al. examined 2682 Finnish men between 42 and
60 years old. The participants were divided into three cat-
egories depending on dietary folate intake (38). After con-
trolling for confounding variables, such as smoking, alco-
hol consumption, body mass index, and socioeconomic
status, people who had low levels of folate in their diet were
found to be more likely to be affected by depression 67%
higher compared to those who had higher levels of folate
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intake (38).
Another study conducted by Morris et al. in the United
States involved 3010 individuals selected from the general
population who were between 15 and 39 years old. Follow-
ing an adjustment for confounding factors, people with de-
pression were determined to have significantly lower lev-
els of serum folate. Additionally, people with dysthymia
showed lower levels of folate serum than the normal pop-
ulation (39). The consistent results of these two studies,
which targeted two different age ranges, demonstrates a
causal relationship between folic acid and depression.
Whether poor nutrition is a symptom of depression
causes folate deficiency or primary folate deficiency pro-
duces depression, folate prescription would be beneficial
and folic acid supplementation would improve the treat-
ment process of depression even in patients without folic
acid deficiency (34, 37, 39, 40).
Although the pre- and posttreatment serum levels of
folic acid were not measured in our study, favorable clin-
ical responses were observed after the coadministration
of folic acid with the standard treatment of depression.
Based on previous surveys, high doses of folic acid (15
mg) might cause side effects, including sleep disturbances,
fatigue, restlessness, and hyperactivity, in healthy volun-
teers. Large doses of folate have been reported to be asso-
ciated with low levels of serotonin in the brain within ani-
mal models. Therefore, ascertaining the effective and safe
therapeutic doses of folic acid and its interactions with a
variety of antidepressant treatment regimens is crucial.
Hypotheses have been proposed to explain the role of
folate deficiency in pathogenesis of mood disorders, es-
pecially MDD, but the exact mechanism of this vitamin
in the development and treatment of depression is not
yet fully understood. Folate assists in the formation of
the cofactor for tyrosine hydroxylase and tryptophan hy-
droxylase, which are important enzymes in the synthe-
sis of monoamines that are related to depression, includ-
ing dopamine, serotonin, and epinephrine (41). Another
possible pathway that explains the role of folate in patho-
genesis of MDD involves homocysteine metabolism. Ho-
mocysteine is a nonprotein amino acid that is produced
as a result of a one-carbon metabolism pathway. Several
enzymes are involved in the catabolism of homocysteine,
such as methylenetetrahydrofolate reductase. This en-
zyme requires sufficient amounts of folic acid in order to
function properly (42). Folic acid deficiency results in ele-
vated homocysteine levels, the presence of which has been
associated with different psychological disorders, such as
schizophrenia, bipolar disorder, and MDD (42-44). Folic
acid supplementation in patients with MDD may enhance
their response to treatment through the reduction of ho-
mocysteine serum levels. There is also evidence to indi-
cate that oxidative stress and reduced antioxidant func-
tion play a role in depression (45). Previous studies have
well demonstrated that folic acid increases the total an-
tioxidant capacity in the body. Thus, it can be hypothesized
that folic acid acts via modifying and reducing oxidative
stress to enhance the treatment of patients with MDD (46,
47).
To best of our knowledge, ours is the first study to ad-
dress the effects of adding folic acid to citalopram for the
treatment of depression. One advantage of our study is
that it investigated depression and anxiety disorders si-
multaneously.
Not measuring the folic acid levels in serum and in red
blood cells is one of the limitations of this study. Other lim-
itations include not measuring the levels of oxidants and
the total antioxidant capacity before and after the folate
prescription, which made it impossible to evaluate the ef-
fect of folate on oxidant and antioxidant status, and lack of
a long-term follow-up period to determine the relapse rate
in the study groups.
Further studies are needed to enable more confident
conclusions about the mechanism via measuring the exact
levels of folic acid. Additionally, more work is required to
compare different antidepressant regimens with or with-
out folic acid and also to ascertain the optimum therapeu-
tic dose of folate.
Acknowledgments
The authors are grateful for the participation of the pa-
tients in this study and for the personnel of the psychiatric
ward of Kashan’s Kargarnezhad Hospital.
Footnotes
Funding/Support: Funding support for this study was
provided by the Kashan University of Medical Sciences,
grant number 92003.
Authors’ Contribution: Development of the original
idea: Zahra Sepehrmanesh; study concept and design:
Zahra Sepehrmanesh and Narges Gholampoor; data collec-
tion: Narges Gholampoor; preparation of the manuscript:
Zahra Sepehrmanesh and Narges Gholampoor; revision
of the manuscript: Zahra Sepehrmanesh and Abdollah
Omidi.
References
1. Francesca MM, Efisia LM, Alessandra GM, Marianna A, Giovanni CM.
Misdiagnosed hypomanic symptoms in patients with treatment-
resistant major depressive disorder in Italy: results from the im-
prove study. Clin Pract Epidemiol Ment Health. 2014;10:42–7. doi:
10.2174/1745017901410010042. [PubMed: 24761153].
6 Iran Red Crescent Med J. 2017; 19(2):e33243.
Sepehrmanesh Z et al.
2. Komaram RB, Nukala S, Palla J, Nambaru LR, Kasturi SM. A Compar-
ative Study of Efficacy and Safety of Agomelatine and Escitalopram
in Major Depressive Disorder. J Clin Diagn Res. 2015;9(6):VC05–8. doi:
10.7860/JCDR/2015/12371.6092. [PubMed: 26266196].
3. Eisendrath SJ, Gillung EP, Delucchi KL, Chartier M, Mathalon DH, Sul-
livan JC, et al. Mindfulness-based cognitive therapy (MBCT) versus
the health-enhancement program (HEP) for adults with treatment-
resistant depression: a randomized control trial study protocol.
BMC Complement Altern Med. 2014;14:95. doi: 10.1186/1472-6882-14-95.
[PubMed: 24612825].
4. Valladares A, Dilla T, Sacristan JA. [Depression: a social mortgage.
Latest advances in knowledge of the cost of the disease]. Actas Esp
Psiquiatr. 2009;37(1):49–53. [PubMed: 18781410].
5. Ferrari AJ, Somerville AJ, Baxter AJ, Norman R, Patten SB, Vos T, et al.
Global variation in the prevalence and incidence of major depressive
disorder: a systematic review of the epidemiological literature. Psy-
chol Med. 2013;43(3):471–81. doi: 10.1017/S0033291712001511. [PubMed:
22831756].
6. Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC. The eco-
nomic burden of adults with major depressive disorder in the
United States (2005 and 2010). J Clin Psychiatry. 2015;76(2):155–62. doi:
10.4088/JCP.14m09298. [PubMed: 25742202].
7. Smagula SF, Butters MA, Anderson SJ, Lenze EJ, Dew MA, Mulsant BH, et
al. Antidepressant Response Trajectories and Associated Clinical Prog-
nostic Factors Among Older Adults. JAMA Psychiatry. 2015;72(10):1021–
8. doi: 10.1001/jamapsychiatry.2015.1324. [PubMed: 26288246].
8. Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Moller HJ, et al.
World Federation of Societies of Biological Psychiatry (WFSBP) guide-
lines for biological treatment of unipolar depressive disorders, part
1: update 2013 on the acute and continuation treatment of unipo-
lar depressive disorders. World J Biol Psychiatry. 2013;14(5):334–85. doi:
10.3109/15622975.2013.804195. [PubMed: 23879318].
9. Yaremco E, Inglis A, Innis SM, Hippman C, Carrion P, Lamers Y, et
al. Red blood cell folate levels in pregnant women with a history
of mood disorders: a case series. Birth Defects Res A Clin Mol Teratol.
2013;97(6):416–20. doi: 10.1002/bdra.23144. [PubMed: 23760977].
10. Issac TG, Soundarya S, Christopher R, Chandra SR. Vitamin B12
deficiency: an important reversible co-morbidity in neuropsychi-
atric manifestations. Indian J Psychol Med. 2015;37(1):26–9. doi:
10.4103/0253-7176.150809. [PubMed: 25722508].
11. Lang UE, Beglinger C, Schweinfurth N, Walter M, Borgwardt S. Nutri-
tional aspects of depression. Cell Physiol Biochem. 2015;37(3):1029–43.
doi: 10.1159/000430229. [PubMed: 26402520].
12. Assies J, Mocking RJ, Lok A, Koeter MW, Bockting CL, Visser I,
et al. Erythrocyte fatty acid profiles and plasma homocysteine,
folate and vitamin B6 and B12 in recurrent depression: Impli-
cations for co-morbidity with cardiovascular disease. Psychiatry
Res. 2015;229(3):992–8. doi: 10.1016/j.psychres.2015.06.025. [PubMed:
26260568].
13. Pourghassem Gargari B, Saboktakin M, Mahboob S, Pourafkari N. Nu-
tritional status in patients with major depressive disorders: a pi-
lot study in tabriz, iran. Health Promot Perspect. 2012;2(2):145–52. doi:
10.5681/hpp.2012.017. [PubMed: 24688928].
14. Su KP, Wang SM, Pae CU. Omega-3 polyunsaturated fatty acids for ma-
jor depressive disorder. Expert Opin Investig Drugs. 2013;22(12):1519–34.
doi: 10.1517/13543784.2013.836487. [PubMed: 24083675].
15. Hintikka J, Tolmunen T, Tanskanen A, Viinamaki H. High vitamin B12
level and good treatment outcome may be associated in major de-
pressive disorder. BMC Psychiatry. 2003;3:17. doi: 10.1186/1471-244X-3-17.
[PubMed: 14641930].
16. Nowak G. Zinc, future mono/adjunctive therapy for depression:
Mechanisms of antidepressant action. Pharmacol Rep. 2015;67(3):659–
62. doi: 10.1016/j.pharep.2015.01.015. [PubMed: 25933983].
17. Venkatasubramanian R, Kumar CN, Pandey RS. A randomized double-
blind comparison of fluoxetine augmentation by high and low
dosage folic acid in patients with depressive episodes. J Affect Disord.
2013;150(2):644–8. doi: 10.1016/j.jad.2013.02.029. [PubMed: 23507369].
18. Passeri M, Cucinotta D, Abate G, Senin U, Ventura A, Stramba Badi-
ale M, et al. Oral 5’-methyltetrahydrofolic acid in senile organic men-
tal disorders with depression: results of a double-blind multicenter
study. Aging (Milano). 1993;5(1):63–71. [PubMed: 8257478].
19. Coppen A, Bailey J. Enhancement of the antidepressant action of flu-
oxetine by folic acid: a randomised, placebo controlled trial. J Affect
Disord. 2000;60(2):121–30. [PubMed: 10967371].
20. Alpert JE, Mischoulon D, Rubenstein GE, Bottonari K, Nierenberg AA,
Fava M. Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-
refractory depression. Ann Clin Psychiatry. 2002;14(1):33–8. [PubMed:
12046638].
21. Taylor MJ, Carney SM, Goodwin GM, Geddes JR. Folate for de-
pressive disorders: systematic review and meta-analysis of ran-
domized controlled trials. J Psychopharmacol. 2004;18(2):251–6. doi:
10.1177/0269881104042630. [PubMed: 15260915].
22. Lerner V, Kanevsky M, Dwolatzky T, Rouach T, Kamin R, Miodownik
C. Vitamin B12 and folate serum levels in newly admitted psychiatric
patients. Clin Nutr. 2006;25(1):60–7. doi: 10.1016/j.clnu.2005.08.014.
[PubMed: 16216392].
23. Papakostas GI, Shelton RC, Zajecka JM, Etemad B, Rickels K, Clain
A, et al. L-methylfolate as adjunctive therapy for SSRI-resistant
major depression: results of two randomized, double-blind,
parallel-sequential trials. Am J Psychiatry. 2012;169(12):1267–74.
doi: 10.1176/appi.ajp.2012.11071114. [PubMed: 23212058].
24. Christensen H, Aiken A, Batterham PJ, Walker J, Mackinnon AJ, Fenech
M, et al. No clear potentiation of antidepressant medication ef-
fects by folic acid+vitamin B12 in a large community sample. J Af-
fect Disord. 2011;130(1-2):37–45. doi: 10.1016/j.jad.2010.07.029. [PubMed:
20805005].
25. Nahas R, Sheikh O. Complementary and alternative medicine for
the treatment of major depressive disorder. Can Fam Physician.
2011;57(6):659–63. [PubMed: 21673208].
26. Sanchez-Villegas A, Henriquez P, Bes-Rastrollo M, Doreste J. Mediter-
ranean diet and depression. Public Health Nutr. 2006;9(8A):1104–9. doi:
10.1017/S1368980007668578. [PubMed: 17378948].
27. Astorg P, Couthouis A, de Courcy GP, Bertrais S, Arnault N, Mene-
ton P, et al. Association of folate intake with the occurrence of
depressive episodes in middle-aged French men and women. Br
J Nutr. 2008;100(1):183–7. doi: 10.1017/S0007114507873612. [PubMed:
18062830].
28. Murakami K, Mizoue T, Sasaki S, Ohta M, Sato M, Matsushita Y, et al. Di-
etary intake of folate, other B vitamins, and omega-3 polyunsaturated
fatty acids in relation to depressive symptoms in Japanese adults.
Nutrition. 2008;24(2):140–7. doi: 10.1016/j.nut.2007.10.013. [PubMed:
18061404].
29. Bjelland I, Tell GS, Vollset SE, Refsum H, Ueland PM. Folate, vitamin
B12, homocysteine, and the MTHFR 677C->T polymorphism in anxi-
ety and depression: the Hordaland Homocysteine Study. Arch Gen Psy-
chiatry. 2003;60(6):618–26. doi: 10.1001/archpsyc.60.6.618. [PubMed:
12796225].
30. Ramos MI, Allen LH, Haan MN, Green R, Miller JW. Plasma fo-
late concentrations are associated with depressive symptoms in el-
derly Latina women despite folic acid fortification. Am J Clin Nutr.
2004;80(4):1024–8. [PubMed: 15447915].
31. Bottiglieri T, Reynolds EH, Laundy M. Folate in CSF and age. J Neurol
Neurosurg Psychiatry. 2000;69(4):562. [PubMed: 11183038].
32. Wolters M, Strohle A, Hahn A. [Age-associated changes in the
metabolism of vitamin B(12) and folic acid: prevalence, aetiopatho-
genesis and pathophysiological consequences]. Z Gerontol Geri-
atr. 2004;37(2):109–35. doi: 10.1007/s00391-004-0169-6. [PubMed:
15103481].
33. Reynolds EH. Benefits and risks of folic acid to the nervous system. J
Neurol Neurosurg Psychiatry. 2002;72(5):567–71. [PubMed: 11971038].
34. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds
Iran Red Crescent Med J. 2017; 19(2):e33243. 7
Sepehrmanesh Z et al.
EH. Homocysteine, folate, methylation, and monoamine metabolism
in depression. J Neurol Neurosurg Psychiatry. 2000;69(2):228–32.
[PubMed: 10896698].
35. Miller AL. The methylation, neurotransmitter, and antioxidant
connections between folate and depression. Altern Med Rev.
2008;13(3):216–26. [PubMed: 18950248].
36. Alpert JE, Mischoulon D, Nierenberg AA, Fava M. Nutrition and de-
pression: focus on folate. Nutrition. 2000;16(7-8):544–6. [PubMed:
10906550].
37. Alpert JE, Fava M. Nutrition and depression: the role of folate. Nutr Rev.
1997;55(5):145–9. [PubMed: 9212690].
38. Tolmunen T, Voutilainen S, Hintikka J, Rissanen T, Tanskanen A, Viina-
maki H, et al. Dietary folate and depressive symptoms are associated
in middle-aged Finnish men. J Nutr. 2003;133(10):3233–6. [PubMed:
14519816].
39. Morris MS, Fava M, Jacques PF, Selhub J, Rosenberg IH. Depres-
sion and folate status in the US Population. Psychother Psychosom.
2003;72(2):80–7. doi: 10.1159/000068692. [PubMed: 12601225].
40. Gariballa S, Forster S. Effects of dietary supplements on de-
pressive symptoms in older patients: a randomised double-
blind placebo-controlled trial. Clin Nutr. 2007;26(5):545–51. doi:
10.1016/j.clnu.2007.06.007. [PubMed: 17662509].
41. Stahl SM. L-methylfolate: a vitamin for your monoamines. J Clin Psy-
chiatry. 2008;69(9):1352–3. [PubMed: 19193337].
42. Moustafa AA, Hewedi DH, Eissa AM, Frydecka D, Misiak B. Homocys-
teine levels in schizophrenia and affective disorders-focus on cogni-
tion. Front Behav Neurosci. 2014;8:343. doi: 10.3389/fnbeh.2014.00343.
[PubMed: 25339876].
43. Ghanizadeh A, Singh AB, Berk M, Torabi-Nami M. Homocysteine as a
potential biomarker in bipolar disorders: a critical review and sug-
gestions for improved studies. Expert Opin Ther Targets. 2015;19(7):927–
39. doi: 10.1517/14728222.2015.1019866. [PubMed: 25882812].
44. Kontoangelos K, Papageorgiou CC, Raptis AE, Tsiotra P, Lambadiari
V, Papadimitriou GN, et al. Homocysteine, cortisol, diabetes mel-
litus, and psychopathology. J Diabetes Res. 2015;2015:354923. doi:
10.1155/2015/354923. [PubMed: 25722989].
45. Liu T, Zhong S, Liao X, Chen J, He T, Lai S, et al. A Meta-Analysis of Ox-
idative Stress Markers in Depression. PLoS One. 2015;10(10):e0138904.
doi: 10.1371/journal.pone.0138904. [PubMed: 26445247].
46. Budni J, Zomkowski AD, Engel D, Santos DB, dos Santos AA, Moretti M,
et al. Folic acid prevents depressive-like behavior and hippocampal
antioxidant imbalance induced by restraint stress in mice. Exp Neu-
rol. 2013;240:112–21. doi: 10.1016/j.expneurol.2012.10.024. [PubMed:
23142187].
47. Aghamohammadi V, Gargari BP, Aliasgharzadeh A. Effect of folic acid
supplementation on homocysteine, serum total antioxidant capac-
ity, and malondialdehyde in patients with type 2 diabetes mellitus. J
Am Coll Nutr. 2011;30(3):210–5. [PubMed: 21896879].
8 Iran Red Crescent Med J. 2017; 19(2):e33243.
